• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

传递:将有癌症病史的供体废弃肝脏用于无法获得标准分配的患者——一项同情使用探索性研究。

TRANSMIT: Utilizing discarded livers from donors with a history of cancer for patients lacking access to standard allocation - A compassionate use exploratory study.

作者信息

Koch Dominik Thomas, Schirren Malte, Jacobi Severin, Lange Christian, Werner Jens, Koliogiannis Dionysios, Guba Markus

机构信息

Department of General, Visceral and Transplant Surgery, LMU University Hospital, LMU, Munich, Germany.

Department of Internal Medicine II, LMU University Hospital, LMU, Munich, Germany.

出版信息

Contemp Clin Trials Commun. 2025 Feb 22;44:101465. doi: 10.1016/j.conctc.2025.101465. eCollection 2025 Apr.

DOI:10.1016/j.conctc.2025.101465
PMID:40115253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11925528/
Abstract

BACKGROUND

A substantial number of viable donor livers are discarded due to the donor's underlying malignancy. Concurrently, patients with certain liver malignancies - such as unresectable colorectal cancer liver metastases (CRC-LM), unresectable intrahepatic or perihilar cholangiocarcinoma (iCCC/phCCC), or unresectable hepatocellular carcinoma (HCC) responding to immunotherapy - often face poor survival outcomes and are deemed ineligible for potentially curative liver transplantation. In this context, a rational risk-benefit analysis suggests that transplanting an organ with a theoretical risk of tumor transmission may be justifiable for these patients facing otherwise short-term fatal outcomes.

METHODS

The TRANSMIT study is a compassionate use exploratory study aimed at assessing the utility and safety of using donor organs from individuals with a current or past history of cancer for liver transplantation in patients with liver malignancies (CRC-LM, i/phCCC, HCC) who are not eligible for regular organ allocation. The study will evaluate the utilization rate of donor organs that would otherwise be discarded, overall survival, progression-free survival, and tumor transmission rates at one and three years, stratified by indication.

DISCUSSION

Donor organs from individuals with a current or past history of cancer may represent a valuable and safe resource for expanding the limited donor pool, particularly for patients who lack access to standard organ allocation.

摘要

背景

相当数量的活体供肝因供体潜在的恶性肿瘤而被丢弃。与此同时,患有某些肝脏恶性肿瘤的患者——如无法切除的结直肠癌肝转移(CRC-LM)、无法切除的肝内或肝门周围胆管癌(iCCC/phCCC),或对免疫疗法有反应的无法切除的肝细胞癌(HCC)——往往面临较差的生存结局,被认为不符合潜在治愈性肝移植的条件。在这种情况下,合理的风险效益分析表明,对于这些面临短期致命结局的患者,移植具有理论上肿瘤传播风险的器官可能是合理的。

方法

TRANSMIT研究是一项同情用药探索性研究,旨在评估将有当前或既往癌症病史个体的供体器官用于不符合常规器官分配条件的肝脏恶性肿瘤(CRC-LM、i/phCCC、HCC)患者肝移植的效用和安全性。该研究将评估否则会被丢弃的供体器官的利用率、总生存期、无进展生存期以及1年和3年时的肿瘤传播率,并按适应症分层。

讨论

有当前或既往癌症病史个体的供体器官可能是扩大有限供体库的宝贵且安全的资源,特别是对于那些无法获得标准器官分配的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34e3/11925528/e5712f0beeaa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34e3/11925528/e5712f0beeaa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34e3/11925528/e5712f0beeaa/gr1.jpg

相似文献

1
TRANSMIT: Utilizing discarded livers from donors with a history of cancer for patients lacking access to standard allocation - A compassionate use exploratory study.传递:将有癌症病史的供体废弃肝脏用于无法获得标准分配的患者——一项同情使用探索性研究。
Contemp Clin Trials Commun. 2025 Feb 22;44:101465. doi: 10.1016/j.conctc.2025.101465. eCollection 2025 Apr.
2
The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden.瑞典中部地区不可切除结直肠癌肝转移患者肝移植中扩大标准供体和合格受者的潜在应用
Hepatobiliary Surg Nutr. 2021 Aug;10(4):476-485. doi: 10.21037/hbsn.2020.03.10.
3
Liver transplantation as an alternative for the treatment of perihilar cholangiocarcinoma: A critical review.肝移植作为肝门部胆管癌治疗的替代方案:一项批判性综述。
Hepatobiliary Pancreat Dis Int. 2024 Apr;23(2):139-145. doi: 10.1016/j.hbpd.2024.01.003. Epub 2024 Jan 20.
4
Oncologic indications of liver transplantation and deceased donor liver allocation in the United States.美国肝移植的肿瘤学适应证和尸体供肝分配。
Curr Opin Organ Transplant. 2021 Apr 1;26(2):168-175. doi: 10.1097/MOT.0000000000000866.
5
Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.新辅助治疗后局部进展期肝内胆管细胞癌行肝移植治疗:一项前瞻性病例系列研究。
Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13.
6
Liver transplantation for hepatic tumors: a systematic review.肝脏肿瘤的肝移植:一项系统综述。
World J Gastroenterol. 2014 May 14;20(18):5345-52. doi: 10.3748/wjg.v20.i18.5345.
7
Liver transplantation in a patient with unresectable colorectal liver metastases -- a case report.不可切除的结直肠癌肝转移患者的肝移植——病例报告
Chirurgia (Bucur). 2013 Sep-Oct;108(5):719-24.
8
The 24-hour normothermic machine perfusion of discarded human liver grafts.废弃人类肝脏移植物的24小时常温机器灌注
Liver Transpl. 2017 Feb;23(2):207-220. doi: 10.1002/lt.24672. Epub 2017 Jan 16.
9
Liver Transplant for Nonhepatocellular Malignancies: A Review for Radiologists.肝移植治疗非肝细胞性恶性肿瘤:放射科医师的综述。
AJR Am J Roentgenol. 2022 Oct;219(4):590-603. doi: 10.2214/AJR.22.27783. Epub 2022 May 11.
10
Declined Organs for Liver Transplantation: A Right Decision or a Missed Opportunity for Patients with Hepatocellular Carcinoma?肝移植被拒绝的器官:对肝细胞癌患者来说是正确的决定还是错失的机会?
Cancers (Basel). 2023 Feb 21;15(5):1365. doi: 10.3390/cancers15051365.

本文引用的文献

1
Donors With Previous Malignancy: When Is It Safe to Proceed With Organ Transplantation?有既往恶性肿瘤病史的供体:何时进行器官移植才安全?
Transpl Int. 2025 Jan 24;38:13716. doi: 10.3389/ti.2025.13716. eCollection 2025.
2
Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.肝移植联合化疗与单纯化疗治疗无法根治性切除的结直肠癌肝转移患者(TransMet):一项多中心、开放标签、前瞻性、随机对照临床试验的结果。
Lancet. 2024 Sep 21;404(10458):1107-1118. doi: 10.1016/S0140-6736(24)01595-2.
3
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.
肝移植前接受免疫治疗的肝细胞癌患者的意向性分析结果:多中心VITALITY研究
J Hepatol. 2025 Mar;82(3):512-522. doi: 10.1016/j.jhep.2024.09.003. Epub 2024 Sep 8.
4
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.移植前免疫检查点抑制剂的使用对肝癌移植后结局的影响:一项系统评价和个体患者数据荟萃分析。
J Hepatol. 2025 Jan;82(1):107-119. doi: 10.1016/j.jhep.2024.06.042. Epub 2024 Jul 10.
5
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.多塔利单抗单药治疗错配修复缺陷型实体瘤患者的抗肿瘤活性和安全性:一项非随机对照试验。
JAMA Netw Open. 2023 Nov 1;6(11):e2341165. doi: 10.1001/jamanetworkopen.2023.41165.
6
Survival Benefit Relative to Treatment Modalities Among Patients with Very Early Intrahepatic Cholangiocarcinoma: an Analysis of the National Cancer Database.极早期肝内胆管癌患者相对于治疗方式的生存获益:一项基于国家癌症数据库的分析
J Gastrointest Surg. 2023 Oct;27(10):2103-2113. doi: 10.1007/s11605-023-05821-7. Epub 2023 Sep 6.
7
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.FOLFOXIRI 联合西妥昔单抗或贝伐珠单抗作为 - 突变型转移性结直肠癌的一线治疗:随机 II 期 FIRE-4.5(AIO KRK0116)研究。
J Clin Oncol. 2023 Sep 1;41(25):4143-4153. doi: 10.1200/JCO.22.01420. Epub 2023 Jun 23.
8
Toronto Management of Initially Unresectable Liver Metastasis from Colorectal Cancer in a Living Donor Liver Transplant Program.多伦多活供肝移植项目中结直肠癌初始不可切除肝转移的管理。
J Am Coll Surg. 2023 Aug 1;237(2):231-242. doi: 10.1097/XCS.0000000000000734. Epub 2023 May 3.
9
Organ Transplants From Deceased Donors With Primary Brain Tumors and Risk of Cancer Transmission.脑肿瘤供者的器官移植与癌症传播风险。
JAMA Surg. 2023 May 1;158(5):504-513. doi: 10.1001/jamasurg.2022.8419.
10
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.纳武利尤单抗联合低剂量伊匹单抗治疗既往治疗后微卫星高度不稳定/错配修复缺陷转移性结直肠癌患者:CheckMate 142 的 4 年随访结果
Ann Oncol. 2022 Oct;33(10):1052-1060. doi: 10.1016/j.annonc.2022.06.008. Epub 2022 Jun 25.